Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow? DOI Open Access
Daniele Masarone, Fabio Valente,

Marina Verrengia

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(22), P. 6867 - 6867

Published: Nov. 14, 2024

Pulmonary hypertension (PH) associated with heart failure preserved ejection fraction (PH-HFpEF) represents a frequent form of PH related to left ventricular dysfunction. The pathophysiology PH-HFpEF is intricate, and varied includes vascular, cardiac, pulmonary factors that contribute synergistically developing this clinical syndrome. Improved knowledge the has paved way for use new drugs such as angiotensin receptor neprilysin inhibitors (ARNIs), non-steroidal mineral corticoid antagonist (nsMRA), sodium-glucose cotransporter (SGLT2is), levosimendan, glucagon-like peptide 1 (GLP-1) agonists. ARNIs are widely used drug treatment reduced fraction. They have also recently been in patients hemodynamic benefits need be confirmed future research. Finerenone an innovative mineralocorticoid exhibits notable cardioprotective renoprotective properties individuals suffering from chronic diabetic kidney disease. It enhances outcomes failure, whether they mildly or Moreover, experimental studies, finerenone found lower artery pressure, reduce muscularization, decrease wall thickness arteries. SGLT2i revolutionized irrespective fraction, their improvement hemodynamics profile PH-HFpEF. Levosimendan inodilator acute advanced failure. In addition, its (supported by positive effects on levosimendan exerts) demonstrated benefit small phase 2 study 3 studies creation oral formulation levosimendan. Finally, GLP1 agonists class that, preliminary evidence, shown effect cardiac hemodynamics, mainly facilitating unloading. These effects, along reduction insulin resistance weight loss, likely lead beneficial patients, especially those obesity comorbidity.

Language: Английский

Transcriptomic Analysis of Arachidonic Acid Pathway Genes Provides Mechanistic Insight into Multi-Organ Inflammatory and Vascular Diseases DOI Open Access
Vaishnavi Aradhyula, Joshua D. Breidenbach,

Bella Khatib-Shahidi

et al.

Genes, Journal Year: 2024, Volume and Issue: 15(7), P. 954 - 954

Published: July 20, 2024

Arachidonic acid (AA) metabolites have been associated with several diseases across various organ systems, including the cardiovascular, pulmonary, and renal systems. Lipid mediators generated from AA oxidation studied to control macrophages, T-cells, cytokines, fibroblasts, regulate inflammatory that induce vascular remodeling dysfunction. is metabolized by cyclooxygenase (COX), lipoxygenase (LOX), cytochrome P450 (CYP) generate anti-inflammatory, pro-inflammatory, pro-resolutory oxidized lipids. As comorbid states such as diabetes, hypertension, obesity become more prevalent in cardiovascular disease, studying expression of pathway genes their association these can provide unique pathophysiological insights. In addition, lipids exhibits diverse functions different where a lipid be both anti-inflammatory pro-inflammatory depending on location metabolic activity. Therefore, we aimed characterize gene enzymes receptors throughout multi-organ via transcriptomic meta-analysis using Gene Expression Omnibus (GEO) Database. our study, found distinct pathways were expressed conditions, especially those prominent risk factors. Comorbidities, appeared contribute elevated mediator genes. Our results demonstrate may potentiate attenuate disease; therefore, suggest further exploration therapeutic targets improve outcomes.

Language: Английский

Citations

3
Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow? DOI Open Access
Daniele Masarone, Fabio Valente,

Marina Verrengia

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(22), P. 6867 - 6867

Published: Nov. 14, 2024

Pulmonary hypertension (PH) associated with heart failure preserved ejection fraction (PH-HFpEF) represents a frequent form of PH related to left ventricular dysfunction. The pathophysiology PH-HFpEF is intricate, and varied includes vascular, cardiac, pulmonary factors that contribute synergistically developing this clinical syndrome. Improved knowledge the has paved way for use new drugs such as angiotensin receptor neprilysin inhibitors (ARNIs), non-steroidal mineral corticoid antagonist (nsMRA), sodium-glucose cotransporter (SGLT2is), levosimendan, glucagon-like peptide 1 (GLP-1) agonists. ARNIs are widely used drug treatment reduced fraction. They have also recently been in patients hemodynamic benefits need be confirmed future research. Finerenone an innovative mineralocorticoid exhibits notable cardioprotective renoprotective properties individuals suffering from chronic diabetic kidney disease. It enhances outcomes failure, whether they mildly or Moreover, experimental studies, finerenone found lower artery pressure, reduce muscularization, decrease wall thickness arteries. SGLT2i revolutionized irrespective fraction, their improvement hemodynamics profile PH-HFpEF. Levosimendan inodilator acute advanced failure. In addition, its (supported by positive effects on levosimendan exerts) demonstrated benefit small phase 2 study 3 studies creation oral formulation levosimendan. Finally, GLP1 agonists class that, preliminary evidence, shown effect cardiac hemodynamics, mainly facilitating unloading. These effects, along reduction insulin resistance weight loss, likely lead beneficial patients, especially those obesity comorbidity.

Language: Английский

Citations

1